“Korea is the only country that has introduced the use of the pharmacoeconomic evaluation exemption system. As an academic, I do not understand the logic of the PE exemption system. It is also difficult to explain to other countries. If a particular drug has received reimbursement at a non-cost effective price due to the system, it will continue to affect latecomers in the indication."

An expert has pointed out that the use of the PE exemption system in place for the reimbursement of drugs approved in Korea should be reduced to a minimum.

The analysis is that if a drug has demonstrated a significant level of clinical benefit or is an ultra-rare disease, the specificity of the drug, such